Clinical Assistant Professor, Pediatric Neurologist, Department of Pediatrics, Faculty of Medicine, University of British Columbia
Medical Director, Pediatric Neuromuscular Program of BC and the Yukon. Investigator at BC Children’s Hospital Research InstituteEmail Kathryn
Read more about Kathryn
Dr. Kathryn Selby is a pediatric neurologist who is involved in acute and chronic clinical care as well as academic and research commitments in neurological and neuromuscular disorders.
Kathryn trained in St. Andrews and Manchester Universities in the UK and subsequently at the University of British Columbia and is the medical director of the pediatric neuromuscular program of British Columbia and the Yukon.
Her main areas of specialist interest are pediatric neuromuscular disorders including spinal muscular atrophy and Duchenne muscular dystrophy and she is involved with neurogenetics and knowledge translation. She plays an active role in medical education and was the former program director for the pediatric neurology program at UBC.
She has also partnered with Doctors of BC and has been involved in the development of long-term care plans for muscle specific disorders in the challenging area of transition of care from pediatric to adult care in children with complex neurological and neuromuscular disorders.
She is actively involved with clinical trials in neuromuscular disorders and in patient advocacy.
In the NMD4C network Kathryn is involved with developing and updating of clinical care guidelines and working with the team for implementation and dissemination and piloting of these guidelines. She is also developing a patient advocacy training module and will support knowledge translation within the neuromuscular community.
Oskoui, M, Gonorazky, H, McMillan, HJ, Dowling, JJ, Amin, R, Gagnon, C et al.. Guidance on gene replacement therapy in Spinal Muscular Atrophy: a Canadian perspective. Can J Neurol Sci. 2021. 1-11 PMID:34082851
Ronsley, R, Islam, N, Kang, M, Nadel, H, Reilly, C, Metzger, D et al.. Effects of Bisphosphonate Therapy on Bone Mineral Density in Boys with Duchenne Muscular Dystrophy. Clin Med Insights Endocrinol Diabetes. 2020.13 1179551420972400 PMID:33335437
Yea, C, Bitnun, A, Branson, HM, Ciftci-Kavaklioglu, B, Rafay, MF, Fortin, O et al.. Association of outcomes in acute flaccid myelitis with identification of enterovirus at presentation: a Canadian, nationwide, longitudinal study. Lancet Child Adolesc Health. 2020.4 (11)828-836 PMID:33068549
Campbell, C, Barohn, RJ, Bertini, E, Chabrol, B, Comi, GP, Darras, BT et al.. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res. 2020.9 (14)973-984 PMID:32851872
White, Z, Hakim, CH, Theret, M, Yang, NN, Rossi, F, Cox, D et al.. High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia. J Clin Lipidol. .14 (4)459-469.e0 PMID:32593511See more on PubMed